Residual Disease in a Novel Xenograft Model of RUNX1-Mutated, Cytogenetically Normal Acute Myeloid Leukemia

Residual Disease in a Novel Xenograft Model of RUNX1-Mutated, Cytogenetically Normal Acute Myeloid Leukemia

Cytogenetically normal acute myeloid leukemia (CN-AML) patients harboring RUNX1 mutations have a dismal prognosis with anthracycline/cytarabine-based chemotherapy. We aimed to develop an in vivo model of RUNX1-mutated, CN-AML in which the nature of residual disease in this molecular disease subset c...

Full description

Bibliographic Details
Main Authors: Sivagnanalingam, Umayal, Balys, Marlene, Eberhardt, Allison, Wang, Nancy, Myers, Jason R., Ashton, John M., Becker, Michael W., Calvi, Laura M., Mendler, Jason H.
Format: Online
Language:English
Published: Public Library of Science 2015
Online Access:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4503761/

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4503761/

Similar Items